Publications by authors named "Hardik Jani"
Article Synopsis
- For vaccines to provide long-lasting immunity and effectiveness, they often require a multi-dose schedule that primes the immune system and boosts its response through repeated doses.
- During the COVID-19 pandemic, 2-dose vaccination regimens were often administered with short intervals to offer quick protection, but studies indicate that longer intervals between doses might enhance immunity durability.
- Research on the mRNA-1273 vaccine in mice found that intervals of 6 to 8 weeks between doses led to higher antibody levels and stronger immune responses, suggesting that longer dosing intervals could be beneficial in non-pandemic contexts.
Article Synopsis
- * Researchers tested two new bivalent vaccines (mRNA-1273.214 and mRNA-1273.222) in mice and found they produced stronger antibody responses against Omicron variants compared to the original vaccine.
- * Administering these bivalent vaccines as boosters significantly improved immune protection and reduced lung infection severity in mice, highlighting their potential effectiveness against circulating strains.
Article Synopsis
- The emergence of SARS-CoV-2 variants in the Omicron lineage has led to reduced vaccine effectiveness and ongoing virus transmission due to the spike protein's ability to evade antibodies.
- Researchers evaluated two bivalent vaccines that include mRNAs for spike proteins from both the original virus and recent variants (BA.1 or BA.4/5) and found they produced stronger immune responses in mice compared to existing monovalent vaccines.
- When used as a booster after initial vaccination, these bivalent vaccines not only generated a more robust antibody response but also provided greater protection against BA.5 infections and reduced inflammation in the lungs.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity.
View Article and Find Full Text PDFSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity.
View Article and Find Full Text PDF